0001209191-23-004118.txt : 20230119 0001209191-23-004118.hdr.sgml : 20230119 20230119200542 ACCESSION NUMBER: 0001209191-23-004118 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230117 FILED AS OF DATE: 20230119 DATE AS OF CHANGE: 20230119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Evanson Jeff CENTRAL INDEX KEY: 0001760511 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 23538689 MAIL ADDRESS: STREET 1: C/O ONCOBIOLOGICS, INC. STREET 2: 7 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-17 0 0001649989 Outlook Therapeutics, Inc. OTLK 0001760511 Evanson Jeff C/O OUTLOOK THERAPEUTICS, INC. 485 ROUTE 1 SOUTH, BLDG F, SUITE 320 ISELIN NJ 08830 0 1 0 0 Chief Commercial Officer Common Stock 2023-01-17 4 S 0 27162 1.31 D 1149968 D Common Stock 2023-01-18 4 S 0 33738 1.25 D 1116230 D Common Stock 2023-01-19 4 S 0 103255 1.22 D 1012975 D These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 75% of the shares as provided in that certain Consulting Agreement dated January 27, 2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from within a $1.00 range. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.1909 - $1.265, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. /s/ Lawrence Kenyon, Attorney-in-Fact 2023-01-19